On Tuesday, Alx Oncology Holdings Inc (NASDAQ: ALXO) opened higher 10.52% from the last session, before settling in for the closing price of $0.44. Price fluctuations for ALXO have ranged from $0.41 to $16.97 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
It was noted that within the last five years, the titan of the Healthcare sector saw sales slided by -35.07%. Company’s average yearly earnings per share was noted 34.41% at the time writing. With a float of $34.03 million, this company’s outstanding shares have now reached $53.38 million.
The extent of productivity of a business whose workforce counts for 80 workers is very important to gauge. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Alx Oncology Holdings Inc (ALXO) Insider and Institutional Ownership
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Alx Oncology Holdings Inc is 36.33%, while institutional ownership is 55.51%. The most recent insider transaction that took place on Feb 19 ’25, was worth 633. In this transaction SVP, FINANCE AND CAO of this company sold 550 shares at a rate of $1.15, taking the stock ownership to the 87,352 shares. Before that another transaction happened on Feb 19 ’25, when Company’s PRESIDENT & CSO sold 1,326 for $1.15, making the entire transaction worth $1,525. This insider now owns 579,388 shares in total.
Alx Oncology Holdings Inc (ALXO) Latest Financial update
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.23 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 34.41% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 25.57% during the next five years compared to -32.29% drop over the previous five years of trading.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Trading Performance Indicators
Check out the current performance indicators for Alx Oncology Holdings Inc (ALXO). In the past quarter, the stock posted a quick ratio of 5.47.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.47, a number that is poised to hit -0.43 in the next quarter and is forecasted to reach -1.32 in one year’s time.
Technical Analysis of Alx Oncology Holdings Inc (ALXO)
The latest stats from [Alx Oncology Holdings Inc, ALXO] show that its last 5-days average volume of 0.63 million was inferior to 0.88 million than last year’s volume. As of the previous 9 days, the stock’s Stochastic %D was 25.43%. Additionally, its Average True Range was 0.06.
During the past 100 days, Alx Oncology Holdings Inc’s (ALXO) raw stochastic average was set at 4.33%, which indicates a significant decrease from 31.10% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 93.69% in the past 14 days, which was lower than the 113.44% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $0.6505, while its 200-day Moving Average is $1.5279. Now, the first resistance to watch is $0.4947. This is followed by the second major resistance level at $0.5083. The third major resistance level sits at $0.5357. If the price goes on to break the first support level at $0.4537, it is likely to go to the next support level at $0.4263. The third support level lies at $0.4127 if the price breaches the second support level.
Alx Oncology Holdings Inc (NASDAQ: ALXO) Key Stats
There are currently 53,396K shares outstanding in the company with a market cap of 25.71 million. Presently, the company’s annual sales total 0 K according to its annual income of -134,850 K. Last quarter, the company’s sales amounted to 0 K and its income totaled -30,750 K.
